Welcome to our dedicated page for Black Diamond Therapeutics SEC filings (Ticker: BDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Black Diamond Therapeutics Inc files regular reports with the SEC that document its clinical development progress, financial position, and strategic decisions. As a clinical-stage biotech company without commercial revenue, Black Diamond's filings focus on research and development expenses, cash runway projections, trial enrollment status, and partnership agreements. Understanding these disclosures helps investors assess the company's ability to fund operations and advance its pipeline.
The company's quarterly 10-Q filings detail cash burn rates, collaboration revenue from licensing agreements, and updates on clinical trial timelines. For clinical-stage companies, management discussion sections provide context on development milestones, regulatory interactions, and decisions regarding resource allocation among pipeline programs. Black Diamond's restructuring activities and strategic focus on lead candidates are documented in these reports, offering transparency into prioritization decisions.
Annual 10-K filings provide comprehensive overviews of Black Diamond's MasterKey platform technology, competitive landscape analysis, and detailed descriptions of each clinical program's mechanism and target populations. Risk factor sections outline challenges specific to precision oncology development, including clinical trial risks, regulatory uncertainty, and competitive threats from companies developing therapies for similar molecular targets. For investors evaluating clinical-stage biotechs, these risk disclosures are essential reading.
Form 4 filings reveal insider transactions by executives and directors, providing signals about management confidence and stock-based compensation activity. Form 8-K documents material events including partnership announcements, clinical hold notifications, and significant financing transactions. Our platform delivers AI-powered summaries that explain complex scientific and financial disclosures in accessible language, helping you quickly understand developments without reading hundreds of pages of technical documentation.
Black Diamond Therapeutics reported that a non-employee director received 5,208 shares of common stock as compensation for annual board service.
The shares were issued on December 12, 2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to take stock instead of cash fees.
The award was valued at $2.76 per share, based on the closing market price on December 11, 2025. Following this grant, the director beneficially owns 86,649 shares directly and has additional indirect interests in shares held by investment funds affiliated with New Enterprise Associates, while disclaiming beneficial ownership of portions in which there is no pecuniary interest.
Black Diamond Therapeutics reported that one of its non-employee directors acquired 4,665 shares of the company’s common stock on December 12, 2025, as reflected in a Form 4 insider trading report.
The shares were issued under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to receive stock instead of cash for annual board service. The value was based on the $2.76 closing market price on December 11, 2025, and the director now beneficially owns 31,027 shares held directly.
Black Diamond Therapeutics filed a shelf registration on Form S-3 to offer, from time to time, up to $500,000,000 of common stock, preferred stock, debt securities, warrants, and/or units. The filing also includes a sales agreement prospectus for an at-the-market program of up to $150,000,000 in common stock under an Open Market Sale AgreementSM with Jefferies LLC, which is part of the $500,000,000 shelf.
Under Rule 415(a)(6), the filing carries forward $400,005,680.55 of unsold securities from a prior shelf (File No. 333-268341); that prior offering will be deemed terminated upon effectiveness of this registration. The company’s common stock trades on Nasdaq as BDTX, and 56,943,413 shares were outstanding as of September 30, 2025. Net proceeds from any future sales are intended for general corporate purposes, including R&D, clinical development, working capital, and capital expenditures.
Black Diamond Therapeutics (BDTX) reported Q3 2025 results showing a net loss of
Cash, cash equivalents and investments totaled about
The Servier deal included a
Black Diamond Therapeutics (BDTX) furnished an 8-K announcing financial results for the three and nine months ended September 30, 2025. The company issued a press release with the details, which is included as Exhibit 99.1. The information was furnished, not filed, under Item 2.02.
Director Behbahani Ali received 4,291 shares of Black Diamond Therapeutics common stock on 09/19/2025 under the companys Fifth Amended and Restated Non-Employee Director Compensation Policy by electing stock in lieu of cash. The report shows a per-share price of $3.35 based on the closing market price on 09/18/2025. After the issuance, the Reporting Persons direct beneficial ownership is reported as 81,441 shares and indirect ownership is reported as 4,448,757 shares through NEA 16, with a disclaimer that the Reporting Person disclaims beneficial ownership of portions where no pecuniary interest exists. The Form 4 discloses the reporting relationship as a director and that the transaction code is an acquisition for director compensation.
Raman Prakash, a non-employee director of Black Diamond Therapeutics, Inc. (BDTX), elected to receive 3,843 shares of the issuer's common stock in lieu of cash for annual director compensation. The shares were issued on 09/19/2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy. After the issuance, the reporting person beneficially owned 26,362 shares. The reported per-share price of $3.35 reflects the closing market price on 09/18/2025. The Form 4 was signed by an attorney-in-fact on 09/22/2025.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
